Robert Paul Hasserjian, M.D.
This page shows the publications co-authored by Robert Hasserjian and Timothy Graubert.
Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia. Blood. 2020 05 14; 135(20):1729-1738.
Case 37-2016. An 86-Year-Old Woman with Leukocytosis and Splenomegaly. N Engl J Med. 2016 12 08; 375(23):2273-2282.
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia. Cancer. 2020 03 15; 126(6):1264-1273.
High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018 06 21; 131(25):2816-2825.
Combined Targeted Therapy for BRAF-Mutant, Treatment-Related Acute Myeloid Leukemia. JCO Precis Oncol. 2017 Nov; 1:1-7.
Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Mol Diagn. 2015 Nov; 17(6):661-8.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.